Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HOOKIPA Pharma Inc.HOOK · Entity 15295 | Director · Chief Executive Officer | August 19, 2025 | October 09, 2025 |
| Tango Therapeutics, Inc.TNGX · Entity 1497 | Director · President & CEO | January 08, 2026 | January 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HOOKIPA Pharma Inc.
Report date August 19, 2025 · Filed October 09, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,347 |
Reported balance
After 2025-08-19 transaction · row 1
1 source rowRow 1 · 2025-08-19 · Sale · Disposed 25,172 · Balance 54,347 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8205 to $0.8225 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8205 to $0.8225 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Tango Therapeutics, Inc.
Report date January 08, 2026 · Filed January 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 367,500 |
Reported balance
After 2026-01-08 transaction · row 1
1 source rowRow 1 · 2026-01-08 · Grant · Acquired 350,000 · Balance 367,500 F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.06 · Expires 2036-01-08 | Direct | 1,650,000 |
Reported balance
After 2026-01-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-08 · Grant · Acquired 1,650,000 · Balance 1,650,000 F2: This option shall vest and become exercisable over a four-year period, with 25% vesting on January 8, 2027 and the remaining option shares vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F2: This option shall vest and become exercisable over a four-year period, with 25% vesting on January 8, 2027 and the remaining option shares vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 08, 2026 Filed Jan 12, 2026 11:15 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 1,650,000 | $0.00 Strike: $11.06 | $0.00 |
DisclosureSEC source: 0001193125-26-009663 · ownership.xml · derivative · entry 2 Peters Malte · CIK 0001876563 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,650,000 Underlying: Common Stock · 1,650,000 shares Expires 2036-01-08 F2 · derivative.exercise_date: This option shall vest and become exercisable over a four-year period, with 25% vesting on January 8, 2027 and the remaining option shares vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 11:15 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantCommon Stock | 350,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-009663 · ownership.xml · nonDerivative · entry 1 Peters Malte · CIK 0001876563 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 367,500 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| November 03, 2025 Filed Nov 4, 2025 14:25 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $8.01 | $0.00 |
DisclosureSEC source: 0001193125-25-263710 · ownership.xml · derivative · entry 1 Peters Malte · CIK 0001876563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-11-03 F1 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments over a period of four years, with the first vesting date on December 3, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| August 19, 2025 Filed Oct 9, 2025 16:22 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | SaleCommon Stock | 25,172 | $0.82 | $20,683.83 |
DisclosureSEC source: 0001876563-25-000004 · form4-10092025_081007.xml · nonDerivative · entry 1 Peters Malte · CIK 0001876563 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,347 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8205 to $0.8225 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 22, 2025 Filed Jul 23, 2025 18:09 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | SaleCommon Stock | 29,176 | $0.92 | $26,841.92 |
DisclosureSEC source: 0001415889-25-020200 · form4-07232025_100740.xml · nonDerivative · entry 1 Peters Malte · CIK 0001876563 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,519 F1 · kind: This sale was affected pursuant to a "sell to cover" arrangement adopted by the Issuer to satisfy the tax withholding obligations triggered by the vesting of restricted stock units granted on July 22, 2024 and does not represent a discretionary trade by the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 21:51 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000950170-25-083912 · ownership.xml · derivative · entry 2 Peters Malte · CIK 0001876563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2035-06-05 F2 · derivative.exercise_date: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 21:51 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083912 · ownership.xml · nonDerivative · entry 1 Peters Malte · CIK 0001876563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 5, 2026 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| July 22, 2024 Filed Jul 24, 2024 16:17 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantCommon Stock | 108,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-020042 · form4-07242024_080713.xml · nonDerivative · entry 1 Peters Malte · CIK 0001876563 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,695 F1 · shares: Grant to the Reporting Person of a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2 · shares: The RSU shall vest in two equal installments on July 22, 2025 and July 22, 2026, subject to the Reporting Person's continuous service through each such date. Read SEC document |
| June 17, 2024 Filed Jun 18, 2024 16:15 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantStock Option (Right to Buy) · Derivative | 49,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001415889-24-017391 · form4-06182024_040618.xml · derivative · entry 1 Peters Malte · CIK 0001876563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,000 Underlying: Common Stock · 49,000 shares Expires 2034-06-17 F1 · derivative.exercise_date: This option award shall vest and become fully exercisable on the earlier to occur of (a) June 17, 2025 and (b) the date of the Issuer's next annual meeting of its stockholders. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:21 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0000950170-24-070906 · ownership.xml · derivative · entry 2 Peters Malte · CIK 0001876563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2034-06-05 F2 · derivative.exercise_date: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year beginning on July 5, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:21 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-070906 · ownership.xml · nonDerivative · entry 1 Peters Malte · CIK 0001876563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,250 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 5, 2025 and (iii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| June 09, 2023 Filed Jun 9, 2023 17:16 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantStock Option (Right to Buy) · Derivative | 52,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001104659-23-070005 · tm2318326-6_4seq1.xml · derivative · entry 1 Peters Malte · CIK 0001876563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2033-06-09 F1 · derivative.exercise_date: One-third of this option shall vest on June 9, 2024, with the remainder vesting in 8 equal quarterly installments thereafter. Read SEC document |
| June 06, 2023 Filed Jun 9, 2023 01:33 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0000899243-23-015014 · doc4.xml · derivative · entry 2 Peters Malte · CIK 0001876563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-06 F2 · derivative.exercise_date: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year beginning on July 6, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| June 06, 2023 Filed Jun 9, 2023 01:33 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-015014 · doc4.xml · nonDerivative · entry 1 Peters Malte · CIK 0001876563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 6, 2024 and (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| June 08, 2022 Filed Jun 28, 2022 20:29 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0000899243-22-024401 · doc4.xml · derivative · entry 1 Peters Malte · CIK 0001876563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year from June 8, 2022, subject to the Reporting Person's continuous service on the board of directors as of each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.